skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 114  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Material Type:
Article
Add to My Research

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156 [Peer Reviewed Journal]

2021 The Authors ;Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.06.002 ;PMID: 34116144

Full text available

2
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
Material Type:
Article
Add to My Research

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer

Breast cancer research and treatment, 2021-01, Vol.185 (1), p.183-194 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2020 ;COPYRIGHT 2021 Springer ;Springer Science+Business Media, LLC, part of Springer Nature 2020. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-020-05935-5 ;PMID: 32980945

Full text available

3
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Material Type:
Article
Add to My Research

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Annals of oncology, 2018-02, Vol.29 (2), p.405-417 [Peer Reviewed Journal]

2017 European Society for Medical Oncology ;The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. 2017 ;The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;ISSN: 1569-8041 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx651 ;PMID: 29092024

Full text available

4
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
Material Type:
Article
Add to My Research

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape

ESMO open, 2021-08, Vol.6 (4), p.100204, Article 100204 [Peer Reviewed Journal]

2021 The Author(s) ;2021 The Author(s) 2021 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2021.100204 ;PMID: 34225076

Full text available

5
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
Material Type:
Article
Add to My Research

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate

Annals of oncology, 2022-03, Vol.33 (3), p.347-349 [Peer Reviewed Journal]

2021 European Society for Medical Oncology ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.11.016 ;PMID: 34861375

Full text available

6
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer
Material Type:
Article
Add to My Research

Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer

Breast cancer research and treatment, 2022-04, Vol.192 (2), p.293-301 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 ;2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. ;COPYRIGHT 2022 Springer ;The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-021-06477-0 ;PMID: 34982322

Full text available

7
Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors
Material Type:
Article
Add to My Research

Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

Supportive care in cancer, 2018-03, Vol.26 (3), p.869-878 [Peer Reviewed Journal]

Springer-Verlag GmbH Germany 2017 ;COPYRIGHT 2018 Springer ;Supportive Care in Cancer is a copyright of Springer, (2017). All Rights Reserved. ;ISSN: 0941-4355 ;EISSN: 1433-7339 ;DOI: 10.1007/s00520-017-3903-5 ;PMID: 28963584

Full text available

8
Scalp cooling in breast cancer patients treated with docetaxel–cyclophosphamide: patient- and nurse-reported results
Material Type:
Article
Add to My Research

Scalp cooling in breast cancer patients treated with docetaxel–cyclophosphamide: patient- and nurse-reported results

Breast cancer research and treatment, 2021-04, Vol.186 (3), p.715-722 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 ;COPYRIGHT 2021 Springer ;The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-020-06063-w ;PMID: 33452953

Full text available

9
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
Material Type:
Article
Add to My Research

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib

ESMO open, 2021-02, Vol.6 (1), p.100018-100018, Article 100018 [Peer Reviewed Journal]

2020 The Author(s) ;2020 The Author(s) 2020 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2020.100018 ;PMID: 33399081

Full text available

10
ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
Material Type:
Article
Add to My Research

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer

ESMO open, 2021-02, Vol.6 (1), p.100017-100017, Article 100017 [Peer Reviewed Journal]

2020 The Author(s) ;2020 The Author(s) 2020 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2020.100017 ;PMID: 33399080

Full text available

11
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
Material Type:
Article
Add to My Research

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer

Breast cancer research and treatment, 2018-08, Vol.171 (1), p.131-141 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2018 ;COPYRIGHT 2018 Springer ;Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-018-4827-6 ;PMID: 29766363

Full text available

12
Risk-reducing mastectomy in BRCA carriers: survival is not the issue
Material Type:
Article
Add to My Research

Risk-reducing mastectomy in BRCA carriers: survival is not the issue

Breast cancer research and treatment, 2020, Vol.179 (1), p.251-252 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2019 ;COPYRIGHT 2020 Springer ;Breast Cancer Research and Treatment is a copyright of Springer, (2019). All Rights Reserved. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-019-05440-4 ;PMID: 31541380

Full text available

13
Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785]
Material Type:
Article
Add to My Research

Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785]

Annals of oncology, 2023-03, Vol.34 (3), p.326-326 [Peer Reviewed Journal]

2022 European Society for Medical Oncology ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2022.11.010 ;PMID: 36529568

Full text available

14
Intrahepatic mitomycin C infusion in breast cancer liver metastases
Material Type:
Article
Add to My Research

Intrahepatic mitomycin C infusion in breast cancer liver metastases

Annals of oncology, 2019-05, Vol.30, p.iii57-iii58 [Peer Reviewed Journal]

2019 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz100.029 ;PMID: 32084862

Full text available

15
Differences between breast cancer subtypes in developing metastatic disease
Material Type:
Article
Add to My Research

Differences between breast cancer subtypes in developing metastatic disease

Annals of oncology, 2019-05, Vol.30, p.iii50-iii50 [Peer Reviewed Journal]

2019 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz100.008 ;PMID: 32084841

Full text available

16
Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival
Material Type:
Article
Add to My Research

Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival

Breast cancer research and treatment, 2019-08, Vol.176 (3), p.597-605 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2019 ;COPYRIGHT 2019 Springer ;Breast Cancer Research and Treatment is a copyright of Springer, (2019). All Rights Reserved. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-019-05254-4 ;PMID: 31065871

Full text available

17
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
Material Type:
Article
Add to My Research

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

ESMO open, 2021-04, Vol.6 (2), p.100058, Article 100058 [Peer Reviewed Journal]

2021 ESMO ;Copyright © 2021 ESMO. Published by Elsevier Ltd.. All rights reserved. ;2021 ESMO 2021 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2021.100058 ;PMID: 33601295

Full text available

18
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
Material Type:
Article
Add to My Research

Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort

Journal of cancer research and clinical oncology, 2021-04, Vol.147 (4), p.1041-1048 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021 ;The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021. ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-020-03487-1 ;PMID: 33471187

Full text available

19
The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
Material Type:
Article
Add to My Research

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

ESMO open, 2022-02, Vol.7 (1), p.100374, Article 100374 [Peer Reviewed Journal]

2021 ;Copyright © 2021. Published by Elsevier Ltd. ;2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. 2021 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2021.100374 ;PMID: 35007996

Full text available

20
Breast cancer subtype and survival by parity and time since last birth
Material Type:
Article
Add to My Research

Breast cancer subtype and survival by parity and time since last birth

Breast cancer research and treatment, 2018-06, Vol.169 (3), p.481-487 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2018 ;COPYRIGHT 2018 Springer ;Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-018-4701-6 ;PMID: 29426984

Full text available

Results 1 - 20 of 114  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (102)

Refine My Results

Creation Date 

From To
  1. Before 2017  (1)
  2. 2017 To 2017  (2)
  3. 2018 To 2018  (8)
  4. 2019 To 2020  (33)
  5. After 2020  (70)
  6. More options open sub menu

Language 

  1. Japanese  (5)
  2. Norwegian  (4)
  3. More options open sub menu

Searching Remote Databases, Please Wait